Successful Treatment of Nivolumab-related Cholangitis with Prednisolone: A Case Report and Review of the Literature-Reference-Cited by-同舟云学术

Successful Treatment of Nivolumab-related Cholangitis with Prednisolone: A Case Report and Review of the Literature

Published:2019-06-15 Issue:12 Volume:58 Page:1747-1752
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Sawada Koji¹,Shonaka Tatsuya²,Nishikawa Yuji³,Hasegawa Kimiharu²,Hayashi Hidemi¹,Hasebe Takumu¹,Nakajima Shunsuke¹,Ikuta Katsuya¹,Fujiya Mikihiro¹,Furukawa Hiroyuki²,Okumura Toshikatsu¹

Affiliation:

1. Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, Japan

2. Division of Gastroenterological and General Surgery, Department of Surgery, Asahikawa Medical University, Japan

3. Division of Tumor Pathology, Department of Pathology, Asahikawa Medical University, Japan

Publisher

Japanese Society of Internal Medicine

Subject

General Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/58/12/58_2330-18/_pdf

Reference27 articles.

1. 1. Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28: 3167-3175, 2010.

2. 2. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366: 2443-2454, 2012.

3. 3. Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32: 1020-1030, 2014.

4. 4. Rizvi NA, Mazières J, Planchard D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol 16: 257-265, 2015.

5. 5. Cella D, Grünwald V, Nathan P, et al. Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial. Lancet Oncol 17: 994-1003, 2016.

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hepatobiliary complications of immune checkpoint inhibitors in cancer;Exploration of Targeted Anti-tumor Therapy;2024-07-26

2. Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCU;Gastroenterología y Hepatología;2024-04

3. Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCU;Gastroenterología y Hepatología (English Edition);2024-04

4. Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH-AEG-SEPD-SEOM-GETECCU;Revista Española de Enfermedades Digestivas;2024

5. Concurrent Nivolumab-Induced Gastritis and Cholangitis Accompanied by Biliary Tract Hemorrhage in a Patient With Stage IV Lung Adenocarcinoma;Cureus;2023-10-02